Navigation Links
Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009
Date:2/17/2009

for the six month period ended December 31, 2008, compared to 73.6% for the corresponding period in 2007.

Operating income for the six month period ended December 31, 2008 totaled $18.8 million, a 39.9% increase from $13.4 million in the corresponding period in 2007. The Company's operating margin kept stable at around 31.0%.

Net income for the six month period ended December 31, 2008 was $8.5 million, $0.41 diluted earnings per share, compared to $8.4 million, $0.53 diluted earnings per share, for the corresponding period in 2007.

Excluding an unrealized net loss on security investments of $1.5 million, and a non-cash charge for amortization of debt discount and issuance costs related to convertible debentures of $2.0 million, non-GAAP adjusted net income for the six months ended December 31, 2008 was $12.0 million, or $1.23 per share, a 38.4% increase from non-GAAP net income of $8.7 million, or $1.46 per share, for the six month period ended December 31, 2007.

Financial Condition

As of December 31, 2008, the Company had $83.0 million in cash and restricted cash. Working capital was $83.7 million, up from $72.5 million as of June 30, 2008. Current liabilities were $33.7 million and long-term debt consisted of $4.0 million in convertible debt. Shareholders' equity was $102.9 million. Future contractual obligations within a one year period include $8.8 million in bank debt and $4.4 million in research and development contractual agreements.

The Company generated $26.4 million in cash flow from operating activities in the first half of the fiscal year 2009, compared to $2.9 million for the first six months of 2007. The Company believes it has enough cash to meet its future cash needs and successfully implement its growth strategies.

Recent Events

In January, the Company announced that it has retained KPMG Huazhen to help the Compan
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
3. AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences
4. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
5. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
6. OmegaGenesis Announces Angiogenesis Application Collaboration
7. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
8. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
9. Cardiogenesis Reports Third Quarter 2008 Results
10. ThermoGenesis Presentation at Rodman & Renshaw Conference
11. Genesis Pharmaceuticals Launches New Corporate Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... Frederick, MD (PRWEB) September 12, 2014 ... systems (LIMS), radio-frequency identification (RFID) solutions and sample ... version 5.1. , RURO completed work on the ... late August and it has already seen mass ... recent major release of version 5.0 brought an ...
(Date:9/11/2014)... team of Berkeley Lab researchers believes it has ... of single atomic layers of transition metal dichalcogenide ... promise for nanoelectronic and photonic applications. , ... of tungsten disulfide, one of the most promising ... existence of excitonic dark states energy states ...
(Date:9/11/2014)... surface of graphene, a one atom thick sheet of ... graphene oxide; a form of graphene that could have ... industries. Applied as paint, it could provide an ultra-strong, ... , Graphene oxide solutions can be used to ... even conventional bricks. After a simple chemical treatment, the ...
(Date:9/11/2014)... Sept. 11, 2014 XBiotech announced today it ... machine that the Company says will be used to ... system is designed to fill, stopper and crimp vials, ... Additionally, the unit is said to contain an in-line ... provide a high level of quality compared to less ...
Breaking Biology Technology:Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3Graphene paints a corrosion-free future 2
... Press Ganey Associates, Inc. has announced its elite class ... the first-ever Summit and Top Improver awards for clinical ... Medical Centers. Press Ganey, the health ... more than 10,000 health care organizations worldwide to create ...
... Calif., Nov. 15, 2011 Quest Diagnostics Incorporated (NYSE: ... diagnostic testing, information and services, today announced that its ... Cytomegalovirus (CMV) molecular test kit on the 3M™ Integrated ... The test is designed to enable hospital labs to ...
... AURORA, Colo., Nov. 15, 2011 In a strategic ... Redevelopment Authority (FRA) has completed a regimen of planning ... allocation of resources going forward. The announcement is made ... "Our first tactic in refocus involves augmenting our board ...
Cached Biology Technology:Nation's Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey 2Nation's Best Health Care Organizations for Patient Satisfaction, Core Measures Honored by Press Ganey 3Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe 2Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe 3Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors 2
(Date:9/11/2014)... professor of mechanical engineering at Worcester Polytechnic ... university,s Integrative Materials Design Center (iMdc), has ... National Science Foundation (NSF) to support the ... metal-ceramic composites, which can be used to ... while significantly increasing their performance. , The ...
(Date:9/11/2014)... 11, 2014 UT Southwestern Medical Center, 2M Companies, ... research and drug development for neurodegenerative disorders caused by ... week, UT Southwestern researchers published a new paper about ... has been shown to help in various animal models ... to Dallas-based 2M Companies. 2M and Calico have now ...
(Date:9/11/2014)... In a study that sheds light on the ... of South America, LSU Museum of Natural Science Director ... Biological Sciences, Robb Brumfield, and an international team of ... published a paper this week challenging the view that ... formed is directly linked to geological and climatic ...
Breaking Biology News(10 mins):NSF funds new method for making materials that can make lighter, more efficient vehicles 2NSF funds new method for making materials that can make lighter, more efficient vehicles 3Calico enters into exclusive collaboration with 2M to develop UTSW technology 2Calico enters into exclusive collaboration with 2M to develop UTSW technology 3LSU scientists lead research on speciation in the tropics 2
... Ivaska (University of Turku and VTT Technical Research Centre of ... National Institute for Health and Welfare) have discovered that the ... a leading journal, the study concludes that SHARPIN regulates the ... prostate cancer cells. It is likely that the discovery will ...
... risk of extinction is a complicated task, especially for species ... University of Georgia and Tulane University have developed a mathematical ... appears in the early online edition of the Royal Society ... for a lot of species, we don,t know very much ...
... might lead to the development of better intervention methods, according ... published in the journal Substance Use & Misuse ... prompted college students to recall their smoking experience, and that ... and on weekends. "Students are using social events ...
Cached Biology News:New model more accurately describes migratory animals' extinction risk 2Research reveals when and why students smoke in effort to help them quit 2
... Zyagen tissue microarrays are derived from ... to rigorous quality control procedures to ensure ... are manually assembled in one block, sectioned ... mounted on coated slides. Sections are large ...
... Zyagen tissue microarrays are derived from frozen ... rigorous quality control procedures to ensure the ... manually assembled in one block, sectioned at ... coated slides. Sections are large (3-5mm in ...
... The DNA Engine Opticon real-time PCR detection ... for fluorescence excitation (450-495 nm) and a ... The Opticon system is built on an ... a thermal gradient feature. This item includes ...
... for Optimal Microdissection , CapSure HS and ... and rapid extraction of populations of pure ... with Laser Capture Microdissection., Ensure the ... Analysis , All CapSure LCM Caps have ...
Biology Products: